Washington, D.C., United States, November 19, 2026
The Lupus Foundation of America (LFA) has announced encouraging findings from its supported Phase II Mesenchymal Stromal Cells in Systemic Lupus Erythematosus (MiSLE) clinical trial, investigating umbilical cord-derived mesenchymal stromal cells (MSCs) as a potential treatment for people with difficult-to-control lupus. The study evaluated whether a single intravenous infusion of MSCs could improve disease activity in adults with active systemic lupus erythematosus (SLE) who had not responded adequately to standard treatments. The findings were presented during a late-breaking session at the American College of Rheumatology (ACR) Convergence 2026 on November 10. The trial investigated two different MSC dose levels and compared their outcomes with placebo. Although the combined MSC treatment groups did not achieve statistical significance for the primary efficacy endpoint at Week 24, secondary analyses identified encouraging improvements among participants who received the higher dose. The higher-dose group demonstrated a response rate of 48.1%, compared with 23.1% in the pooled placebo group. These findings provide important information for designing future studies and support further investigation of MSC-based cell therapy as a potential treatment strategy for patients with refractory lupus.
MiSLE Phase II Trial Evaluates Umbilical Cord-Derived MSCs
The MiSLE study is a multicentre, randomised, double-blind, placebo-controlled Phase II clinical trial and represents an important investigation of allogeneic umbilical cord-derived mesenchymal stromal cells in adults with active SLE. The trial enrolled participants across nine clinical centres in the United States. Of the 87 participants randomised, 81 received an infusion: 27 received the lower MSC dose of one million cells per kilogram, 27 received the higher dose of five million cells per kilogram, and 27 received placebo. All participants continued to receive standard-of-care treatment alongside the investigational intervention. The primary endpoint was the proportion of patients achieving a response at Week 24 according to a modified Systemic Lupus Erythematosus Responder Index-4 (SRI-4). This assessment combines improvements in disease activity with requirements that prevent significant worsening in other disease measures and limit steroid and immunosuppressant use. In the overall analysis, 38.9% of MSC-treated participants achieved the primary response compared with 23.1% of placebo recipients. However, the difference did not reach statistical significance (adjusted p=0.156). This means the study did not meet its primary endpoint, making the secondary findings particularly important for planning additional research.
Higher MSC Dose Shows Encouraging Disease Response
Secondary analyses identified a stronger response among patients receiving the higher MSC dose. At Week 24, the response rate was 48.1% in the five-million-cells-per-kilogram group, compared with 29.6% in the lower-dose group and 23.1% in the pooled placebo group. The higher-dose comparison approached statistical significance (adjusted p=0.054), suggesting a potentially meaningful dose-related treatment effect that requires confirmation. Additional analyses using the unmodified SRI-4 measure identified earlier response signals at Weeks 12, 16 and 20 in the higher-dose group compared with its corresponding placebo cohort. In a per-protocol analysis, which excluded participants with major protocol deviations, the Week 24 response was 68.4% among higher-dose recipients compared with 30.0% in the pooled placebo group (adjusted p=0.0087). Researchers also evaluated changes in SLE Disease Activity Index (SLEDAI) scores, which measure the severity of lupus activity. Disease activity declined across all three study groups, with the higher-dose group demonstrating a greater median reduction at Week 24. These results suggest that the higher MSC dose may warrant further investigation, although secondary and per-protocol findings should be interpreted cautiously because they do not replace the unsuccessful primary endpoint.
Safety Findings Support Further Cell Therapy Research
Safety was assessed through Week 52. The study reported that none of the serious adverse events were attributed to the investigational MSC treatment. Serious adverse events occurred in 27.8% of participants receiving MSCs overall, compared with 14.8% in the placebo group. The incidence differed between dose cohorts, with a lower reported rate in the higher-dose group than in the lower-dose group. Serious infections occurred in 7.4% of MSC-treated participants and 3.7% of placebo recipients. These findings will require continued monitoring in larger studies. MSCs are being investigated for their ability to regulate immune responses and potentially reduce abnormal inflammatory activity. In lupus, the immune system mistakenly attacks the body’s own tissues and organs, causing inflammation that can affect the kidneys, skin, joints, heart and other systems. The Lupus Foundation of America has supported MSC research since 2012, including a $3.8 million commitment announced in 2018 for the Phase II programme. Based on the findings, investigators are developing a confirmatory trial focused on the higher five-million-cells-per-kilogram dose, with repeat dosing also being considered to determine whether treatment responses can be maintained. Further research will be essential to establish long-term safety, efficacy and the potential clinical role of MSC therapy in refractory lupus.
Source: Lupus Foundation of America press release



